Latest Breaking News On - Preston klassen - Page 1 : comparemela.com

Regulus Therapeutics (RGLS) Reports Positive Topline Data from the Second Cohort in Phase 1b Trial of RGLS8429

Regulus Therapeutics (RGLS) Reports Positive Topline Data from the Second Cohort in Phase 1b Trial of RGLS8429
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Preston klassenAlan yuJay haganRegulus therapeutics incUniversity of kansas medical centerHead of research development regulusRegulus therapeuticsKansas medical

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney.

United statesSan diegoJay haganAlan yuPreston klassenRnas the company or regulusUniversity of kansas medical centerExchange commissionRegulus therapeutics incPrnewswire regulus therapeutics incHead of research development regulusKansas medicalDominant polycystic kidney diseasePrivate securities litigation reform act

Regulus Therapeutics (RGLS) Announces Positive Topline Data from First Cohort of Patients in its Phase 1b MAD Clinical Trial of RGLS8429 for Treatment of ADPKD

Regulus Therapeutics (RGLS) Announces Positive Topline Data from First Cohort of Patients in its Phase 1b MAD Clinical Trial of RGLS8429 for Treatment of ADPKD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jay haganPreston klassenHead of research developmentRnas the company or regulusRegulus therapeutics incRegulus therapeutics

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesPreston klassenJay haganHead of research developmentExchange commissionRnas the company or regulusPrnewswire regulus therapeutics incRegulus therapeutics incPolycystic kidney diseasePrivate securities litigation reform act

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoOleg butovskyJay haganPrestons klassenLou gehrigPreston klassenHowardl weinerCurtisa monnigExchange commissionFoundation for neurologic diseases bostonOrexigen therapeuticsProgram updatesRnas the company or regulusDevelopment leadershipRegulus therapeutics inc